Cullen/Frost Bankers’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cullen/Frost Bankers’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4	Closed	-$1.09K	–	1234
2024 Q2	$1.09K	Sell	4 -5	-56%	-$1.45K	﹤0.01%	1178
2024 Q1	$3.11K	Hold	9	–	–	﹤0.01%	901
2023 Q4	$2.91K	Hold	9	–	–	﹤0.01%	917
2023 Q3	$3.23K	Hold	9	–	–	﹤0.01%	1031
2023 Q2	$3.41K	Buy	+9	New	+$3.66K	﹤0.01%	1010
2023 Q1	–	Sell	-2	Closed	-$841	–	1205
2022 Q4	$841	Hold	2	–	–	﹤0.01%	1056
2022 Q3	$1K	Buy	+2	New	+$997	﹤0.01%	1072
2022 Q2	–	Sell	-2	Closed	-$1K	–	1075
2022 Q1	$1K	Hold	2	–	–	﹤0.01%	1080
2021 Q4	$2K	Buy	+2	New	+$1.5K	﹤0.01%	1073
2020 Q1	–	Sell	-136	Closed	-$50K	–	912
2019 Q4	$50K	Buy	136 +73	+116%	+$25.7K	﹤0.01%	591
2019 Q3	$21K	Buy	63 +24	+62%	+$7.83K	﹤0.01%	704
2019 Q2	$12K	Buy	+39	New	+$11.7K	﹤0.01%	791

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cullen/Frost Bankers's BIO Position: Q3 2024 in Review

Cullen/Frost Bankers sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 4 shares — an estimated $1.09K sold.

Cullen/Frost Bankers first reported a position in BIO in Q2 2019 and held it in 12 quarters. The position peaked at $50K in Q4 2019. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Cullen/Frost Bankers reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
Cullen/Frost Bankers sold 4 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $1.09K.
Cullen/Frost Bankers first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 12 quarters.
Cullen/Frost Bankers's Bio-Rad Laboratories Class A position peaked at $50K in Q4 2019.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Cullen/Frost Bankers's 13F filing for Q3 2024, filed 6 Nov 2024.